Press release
Investigation announced for Investors in shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC)
An investigation on behalf of current long term investors in LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares.
Investors who are current long term investors in LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LOGC stocks follows a lawsuit filed against LogicBio Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: LOGC stocks, concerns whether certain LogicBio Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that: LogicBio's behind-schedule and rushed Investigational New Drug ("IND") submission of LB-001 did not answer certain pertinent clinical and nonclinical questions, that as a result, the U.S. Food and Drug Administration was likely to hold or deny the IND submission of LB-001 for treatment of methylmalonic acidemia (MMA), and that as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) have certain options and should contact the Shareholders Foundation.
Media Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) here
News-ID: 2069894 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for LogicBio
Propionic Acidemia Therapeutic Market: With CAGR of 7.8% by 2031 Market Size & S …
According to a new report published by CoherentMI The propionic acidemia therapeutic market is estimated to be valued at USD 600.6 Mn in 2024 and is expected to reach USD 1,016.6 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.
Most recent Report, named "Propionic Acidemia Therapeutic Market" Patterns, Offer, Size, Development, Opportunity and Forecast 2024-2031, by CoherentMI offers a complete investigation…
Robust Growth in Propionic Acidemia Therapeutic Market (2024-2031): Industry Ins …
CoherentMI has added a new research study on the Global "Propionic Acidemia Therapeutic Market" 2024 by Size, Growth, Trends, and Dynamics, Forecast to 2031 which is a result of an extensive examination of the market patterns. This report covers a comprehensive investigation of the information that influences the market regarding fabricates, business providers, market players, and clients. The report provides data about the aspects which drive the expansion of the…
Methylmalonic Acidemia Market to Show a Rise During the Forecast Period asserts …
DelveInsight's "Methylmalonic Acidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Methylmalonic Acidemia, historical and forecasted epidemiology as well as the Methylmalonic Acidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Methylmalonic Acidemia market report provides current treatment practices, emerging drugs, Methylmalonic Acidemia market share of the individual therapies, and current and forecasted Methylmalonic Acidemia market size…
Methylmalonic Acidemia Pipeline Assessment (2023) Covering Clinical Trials, Emer …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Methylmalonic Acidemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Methylmalonic Acidemia Pipeline Insight, 2023" report…
Deadline on May 18th upcoming in Lawsuit for Investors in LogicBio Therapeutics, …
A deadline is coming up on May 18, 2020 in the lawsuit filed for certain investors of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) over alleged securities laws violations by LogicBio Therapeutics, Inc.
Investors who purchased shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) have certain options and there are strict and short deadlines running. Deadline: May 18, 2020. NASDAQ: LOGC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
Lawsuit filed for Investors in shares of LogicBio Therapeutics, Inc. (NASDAQ: LO …
An investor, who purchased shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), filed a lawsuit over alleged violations of Federal Securities Laws by LogicBio Therapeutics, Inc..
Investors who purchased shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) have certain options and for certain investors are short and strict deadlines running. Deadline: May 18, 2020. NASDAQ: LOGC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Cambridge, MA based LogicBio…
